Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study)-Reference-Cited by-同舟云学术

Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study)

Published:2014-08-05 Issue:1 Volume:277 Page:137-150
ISSN:0954-6820
Container-title:Journal of Internal Medicine
language:en
Short-container-title:J Intern Med

Author:

Xu W.¹,Bi Y.²,Sun Z.³,Li J.¹,Guo L.⁴,Yang T.⁵,Wu G.⁶,Shi L.⁷,Feng Z.⁸,Qiu L.⁹,Li Q.¹⁰,Guo X.¹¹,Luo Z.¹²,Lu J.¹³,Shan Z.¹⁴,Yang W.¹⁵,Ji Q.¹⁶,Yan L.¹⁷,Li H.¹⁸,Yu X.¹⁹,Li S.²⁰,Zhou Z.²¹,Lv X.²²,Liang Z.²³,Lin S.²⁴,Zeng L.¹,Yan J.¹,Ji L.²⁵,Weng J.¹

Affiliation:

1. Department of Endocrinology and Metabolism; Guangdong Provincial Key Laboratory of Diabetology; the Third Affiliated Hospital of Sun Yat-sen University; Guangzhou China

2. Department of Endocrinology; Drum Tower Hospital Affiliated to Nanjing University Medical School; Nanjing China

3. Department of Endocrinology; Zhongda Hospital; Institute of Diabetes; Medical School; Southeast University; Nanjing China

4. Department of Endocrinology; Beijing Hospital of the Ministry of Public Health; Beijing China

5. Department of Endocrinology; the First Affiliated Hospital of Nanjing Medical University; Nanjing China

6. Department of Endocrinology; the Affiliated Hospital of Guangdong Medical College; Zhanjiang China

7. Department of Endocrinology; Affiliated Hospital of Guiyang Medical College; Guizhou China

8. Department of Endocrinology; the First Affiliated Hospital; Chongqing Medical University; Chongqing China

9. Department of Endocrinology; the Affiliated Hospital of Inner Mongolia Medical University; Hohhot China

10. Department of Endocrinology; the Second Affiliated Hospital of Harbin Medical University; Harbin China

11. Department of Endocrinology; Peking University First Hospital; Beijing China

12. Department of Endocrinology; the First Affiliated Hospital of Guangxi Medical University; Nanning China

13. Department of Endocrinology; Chinese People's Liberation Army General Hospital; Beijing China

14. Department of Endocrinology; the First Affiliated Hospital of China Medical University; Shenyang China

15. Department of Endocrinology; China-Japan Friendship Hospital; Beijing China

16. Department of Endocrinology and Metabolism; Xijing Hospital affiliated to the Fourth Military Medical University; Xi'an China

17. Department of Endocrinology; Sun Yat-sen Memorial Hospital of Sun Yat-sen University; Guangzhou China

18. Department of Endocrinology; the First Affiliated Hospital of Kunming Medical University; Kunming China

19. Department of Endocrinology; Tongji Hospital; Tongji Medical College of Huazhong University of Science and Technology; Wuhan China

20. Department of Endocrinology; Qingyuan People's Hospital; Qingyuan China

21. Diabetes Centre; Institute of Metabolism and Endocrinology; the Second Xiangya Hospital and Key Laboratory of Diabetes Immunology; Ministry of Education; Central South University; Changsha China

22. Department of Endocrinology; General Hospital of Beijing Military Region; Beijing China

23. Department of Endocrinology; First Affiliated Hospital of Shenzhen University; Shenzhen China

24. Department of Endocrinology; the First Affiliated Hospital; Shantou University Medical College; Shantou China

25. Department of Endocrinology; Peking University People's Hospital; Beijing China

Funder

Ministry of Health of the People's Republic of China

National Science Fund

Eli Lilly and Co.

Amylin Pharmaceuticals, Inc.

Bristol-Myers Squibb

Astra Zeneca

Publisher

Wiley

Subject

Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/joim.12293/fullpdf

Reference32 articles.

1. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes;Kahn;Diabetologia,2003

2. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants;Danaei;Lancet,2011

3. Standards of Medical Care in Diabetes-2013;American Diabetes Association;Diabetes Care,2013

4. Clinical Practice Guidelines: pharmacologic management of Type 2 diabetes;Committee;Can J Diabetes,2013

5. China guideline for type 2 diabetes (2010 edition);Chinese Diabetes Society;Chin J Diabetes,2012

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of changes in adipokine and inflammatory cytokine levels in patients with newly diagnosed type 2 diabetes treated with exenatide, insulin, or pioglitazone: A post-hoc study of the CONFIDENCE trial;Heliyon;2024-01

2. Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials;BMC Medicine;2023-11-16

3. Data-driven subgroups of newly diagnosed type 2 diabetes and the relationship with cardiovascular diseases at genetic and clinical levels in Chinese adults;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2023-09

4. Beta‐cell function in type 2 diabetes (T2DM): Can it be preserved or enhanced?;Journal of Diabetes;2023-07-31

5. GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis;Frontiers in Endocrinology;2023-07-06